Onkologie, Hämatologie - Daten und Informationen

5.1-5.8 Schmerztherapie bei Tumorerkrankungen: Literatur

Autor/en: M. Kloke
Letzte Änderung: 25.01.2006
  • Ahmedzai S, Brooks D.
    Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficiancy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
    J Pain Sympt Manage 1997;13(5):254-61. PM:9185430

  • Ashby M, Fleming B, Wood M, Somogyi PD.
    Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997;14(3):157-167. PM:9291702

  • Arzneimittelkommission der Deutschen Ärzteschaft.
    Arzneiverordnung in der Praxis.
    Tumorschmerzen, 2. Aufl. 2000. http://www.akdae.de/35/93_Tumorschmerzen_2000_2Auflage.pdf

  • Bruera E, Pereira J, Watanbe S et al.
    Opioid rotation in patients with cancer pain A retrospective comparison of dose ratios between methadone, hydromorphone and morphine.
    Cancer 1996;78:852-857. PM:8756381

  • Burera E, Schoeller T, Wenk R et al.
    A prospective multicenter assessment of the Edmonton staging system for cancer pain.
    J Pain Symptom Manage 1995;10:348-355. PM:7673767

  • Deutsche Interdisziplinäre Vereinigung zur Schmerztherapie (DIVS).
    Leitlinien zur Tumorschmerztherapie, Tumordiagnostik und Therapie.
    Tumordiagnostik und Therapie 1998;20.4:105-129.

  • Expert Working Group of EAPC.
    Morphine in cancer pain: modes of administration.
    Br Med J 1996;312:823-826. PM:8608293

  • Expert Working Group of the Research Network of the European Association for Palliative Care.
    Morphine and alternative opioids in cancer pain: the EAPC recommendations.
    BJC 2001;84:587-593. PM:11237376

  • Grond S, Zech D, Schug SA et al.
    Validation of the World Health Organisation guidelines for cancer pain relief during the last days and hours of life.
    J Pain Symptom Manage 1991;6/7:411-422. PM:1940485

  • Hanks GW, De Conno F, Cherny N et al.
    Morphine and alternative opiods in cancer pain: the EAPC recommendations.
    Brit J Cancer 2001;84:587-593. PM:11237376

  • Inturrisi CE.
    Clinical pharmacology of opioids for pain.
    Clin J Pain 2002;18:3-13. PM:12479250

  • Kloke M, Rapp M, Bosse B, Kloke O.
    Toxicity and/or insufficient analgesia by opioid therapy; risk factors and the impact of changing the opioid.
    Supp Care Cancer 2000;8:479-486. PM:11094993

  • Mather LE.
    Trends in the pharmacology of opioids: implications for the pharmacotherapy of pain.
    Eur J Pain 2001;5:49-57. PM:11798218

  • Mercadante S, Arvuri E.
    Opioids and renal function.
    J Pain 2002;5:2-19. PM:14975374

  • Nicholson AB.
    Methadone for cancer pain.
    Cochrane Database Syst Rev 2004;2:CD003971. PM:15106230

  • Paice JA, Toy C, Shott Y.
    Barriers to cancer pain relief: Fear of tolerance and addiction.
    J Pain Symptom Manage 1998;16:1-9. PM:9707652

  • Sutton LM, Porter LS, Keefe FJ.
    Cancer pain at the end of life: a biopsychological perspective.
    Pain 2002;99:5-10. PM:12237179

  • Tegeder I, Lotsch J, Geisslinger G.
    Pharmacokinetics of opioids in liver disease.
    Clin Pharmacokinet 1999;37:17-40. PM:10451781

  • Walsh D, Donelly S, Rybicki L.
    The symptoms of advanced cancer: relationship to age, gender, and performance status in 1000 Patients.
    Supp Care Cancer 2000;8:175-179. PM:10789956

  • World Health Organisation.
    Cancer pain relief.
    Genf: WHO Publishing 1985.

  • World Health Organisation.
    Cancer pain relief, 2nd edn. Genf:
    WHO Publishing 1996.

  • Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA.
    Validation of World Health Organisation guidelines cancer pain relief.
    Pain 1995;63:65-76. PM:8577492

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag